MedTrace Logo

Etanercept (Enbrel®) in Psoriasis - Pediatrics

NCT00078819 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2019-07-29

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and efficacy of etanercept (Enbrel®) in children with Psoriasis.

Conditions

Interventions

DRUG

Etanercept

Etanercept 0.8 mg/kg (up to an intended dose of 50 mg) by subcutaneous injection once a week

DRUG

Placebo

Placebo matching to etanercept administered by subcutaneous injection once a week

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-08
Primary Completion
2006-02-01
Completion
2007-06-01

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00078819 on ClinicalTrials.gov